The collagen-induced arthritis model in DBA/1J mice was used to assess the potential therapeutic utility of FasL-LVP administration, since Fas expression is enhanced on activated lymphocytes and the immunopathogenesis in this model involves both T-cell and B-cell-specific responses to collagen (27). The gene discussed is FAS; the disease is arthritic joint disease.